Cellares And Lyell To Evaluate Automated Manufacturing Of Lyell's CAR T-Cell Therapy On Cellares' Cell Shuttle Platform
Portfolio Pulse from Bill Haddad
Cellares and Lyell are partnering to evaluate the automated manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform. The partnership aims to improve the production process of the therapy.
September 11, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lyell's partnership with Cellares to automate the manufacturing of its CAR T-Cell Therapy could potentially streamline production and improve efficiency.
The partnership with Cellares could potentially streamline Lyell's production process, making it more efficient and cost-effective. This could positively impact Lyell's bottom line and make its therapy more competitive in the market.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70